0001640455-21-000016.txt : 20210122 0001640455-21-000016.hdr.sgml : 20210122 20210122183557 ACCESSION NUMBER: 0001640455-21-000016 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210120 FILED AS OF DATE: 20210122 DATE AS OF CHANGE: 20210122 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Drapkin Kimberlee C CENTRAL INDEX KEY: 0001340881 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37998 FILM NUMBER: 21547394 MAIL ADDRESS: STREET 1: PREDIX PHARMACEUTICALS HOLDINGS, INC. STREET 2: 4 MAGUIRE ROAD CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Jounce Therapeutics, Inc. CENTRAL INDEX KEY: 0001640455 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 454870634 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-259-3840 MAIL ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 wf-form4_161135854303039.xml FORM 4 X0306 4 2021-01-20 0 0001640455 Jounce Therapeutics, Inc. JNCE 0001340881 Drapkin Kimberlee C C/O JOUNCE THERAPEUTICS, INC. 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 0 1 0 0 CFO and Treasurer Common Stock 2021-01-20 4 M 0 3016 0.48 A 58897 D Common Stock 2021-01-20 4 M 0 6775 0.74 A 65672 D Common Stock 2021-01-20 4 M 0 3710 2.36 A 69382 D Common Stock 2021-01-20 4 S 0 16201 12.03 D 53181 D Common Stock 2021-01-20 4 S 0 10000 10.03 D 43181 D Common Stock 2021-01-21 4 M 0 3799 2.36 A 46980 D Common Stock 2021-01-21 4 S 0 3799 12 D 43181 D Stock Option (Right to Buy) 0.48 2021-01-20 4 M 0 3016 0 D 2024-01-27 Common Stock 3016.0 0 D Stock Option (Right to Buy) 0.74 2021-01-20 4 M 0 6775 0 D 2025-01-12 Common Stock 6775.0 0 D Stock Option (Right to Buy) 2.36 2021-01-20 4 M 0 3710 0 D 2025-08-25 Common Stock 3710.0 209804 D Stock Option (Right to Buy) 2.36 2021-01-21 4 M 0 3799 0 D 2025-08-25 Common Stock 3799.0 206005 D The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019, and amended on November 30, 2020. The Reporting Person exercised no discretion with respect to these transactions. Represents the weighted average share price of an aggregate total of 16,201 shares sold in the price range of $12.00 to $12.08 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average share price of an aggregate total of 10,000 shares sold in the price range of $10.00 to $10.12 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average share price of an aggregate total of 3,799 shares sold at $12.00 and $12.01 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. The option shares vested and became exercisable in 12 monthly installments from October 9, 2013. The option shares vested and became exercisable in 12 monthly installments from October 9, 2014. 25% of the option shares vested and became exercisable on August 26, 2016 and the remainder of the option shares vest and become exercisable in 12 quarterly installments thereafter. /s/ Kimberlee C. Drapkin 2021-01-22